- Home
- TNFA vs ZVSA Comparison
TNFA vs ZVSA Comparison
Compare TNFA & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNFA
- ZVSA
- Stock Information
- Founded
- TNFA 2014
- ZVSA 2014
- Country
- TNFA United States
- ZVSA United States
- Employees
- TNFA N/A
- ZVSA N/A
- Industry
- TNFA
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- TNFA
- ZVSA Health Care
- Exchange
- TNFA NYSE
- ZVSA Nasdaq
- Market Cap
- TNFA 3.2M
- ZVSA 3.5M
- IPO Year
- TNFA N/A
- ZVSA N/A
- Fundamental
- Price
- TNFA $0.48
- ZVSA $1.22
- Analyst Decision
- TNFA
- ZVSA Strong Buy
- Analyst Count
- TNFA 0
- ZVSA 1
- Target Price
- TNFA N/A
- ZVSA $240.00
- AVG Volume (30 Days)
- TNFA 852.2K
- ZVSA 69.7K
- Earning Date
- TNFA 03-31-2025
- ZVSA 03-24-2025
- Dividend Yield
- TNFA N/A
- ZVSA N/A
- EPS Growth
- TNFA N/A
- ZVSA N/A
- EPS
- TNFA N/A
- ZVSA N/A
- Revenue
- TNFA N/A
- ZVSA N/A
- Revenue This Year
- TNFA N/A
- ZVSA N/A
- Revenue Next Year
- TNFA N/A
- ZVSA N/A
- P/E Ratio
- TNFA N/A
- ZVSA N/A
- Revenue Growth
- TNFA N/A
- ZVSA N/A
- 52 Week Low
- TNFA $0.45
- ZVSA $0.98
- 52 Week High
- TNFA $3.60
- ZVSA $25.00
- Technical
- Relative Strength Index (RSI)
- TNFA 26.35
- ZVSA 44.26
- Support Level
- TNFA $0.45
- ZVSA $1.12
- Resistance Level
- TNFA $0.66
- ZVSA $1.29
- Average True Range (ATR)
- TNFA 0.09
- ZVSA 0.09
- MACD
- TNFA -0.00
- ZVSA -0.01
- Stochastic Oscillator
- TNFA 7.07
- ZVSA 37.04
About TNFA TNF PHARMACEUTICALS INC EFFEC
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.